Safety, immunogenicity and risk-benefit analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in Phase I-III clinical trials across regions

DSpace Repository

Safety, immunogenicity and risk-benefit analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in Phase I-III clinical trials across regions

Author: Bache, Bache Emmanuel; Grobusch, Martin P.; Agnandji, Selidji Todagbe
Tübinger Autor(en):
Grobusch, Martin
Agnandji, Selidji Todagbe
Published in: Future Microbiology (2020), Bd. 15, H. 2, S. 85-106
Verlagsangabe: Future Medicine Ltd
Language: English
Full text: http://dx.doi.org/10.2217/fmb-2019-0237
ISSN: 1746-0921
DDC Classifikation: 570 - Life sciences; biology
610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)